REDEMPLO's SHTG Phase 3 data will determine whether plozasiran's FCS approval translates into a large-market cardiovascular franchise

Bull

A positive outcome would show statistically significant and clinically meaningful triglyceride reduction (consistent with the 83% median reduction seen in Phase 2b long-term data) with a clean safety profile and meaningful reduction in pancreatitis events, supporting a broad SHTG label. This would validate the One-REDEMPLO pricing model across both indications, dramatically expand the addressable patient population beyond the small FCS market, and position plozasiran as the category-defining APOC3 silencer in high-triglyceride cardiovascular disease.

Bear

The most likely failure modes are a primary endpoint miss on triglyceride reduction that fails to achieve statistical significance in the broader, more heterogeneous SHTG population, or a failure to demonstrate a reduction in adjudicated pancreatitis events sufficient for a strong label claim. A less differentiated safety or efficacy profile relative to olezarsen (Ionis) could also undermine the pricing premium and commercial thesis, while any unexpected adverse events in a larger trial population would be particularly damaging given SHTG's much higher commercial stakes.